Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MV 140

Next Previous
Drug Profile

MV 140

Alternative Names: MV-140; UROMUNE

Latest Information Update: 15 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunotek SL
  • Developer Immunotek SL; Queens University
  • Class Anti-infectives; Bacterial vaccines; Urinary anti-infective agents
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Urinary tract infections

Most Recent Events

  • 02 Feb 2026 Inmunotek plans a phase III trial for Urinary tract infections (Prevention, Recurrent) in Portugal (Sublingual) (CTIS2025-524377-16-00)
  • 03 Oct 2023 Inmunotek SL completes expanded access programme for Urinary tract infections (Recurrent) in Belgium, Czech Republic, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Romania, Serbia, Slovakia, Slovenia, Sweden and Turkey (NCT04173013)
  • 30 Jun 2023 MV 140 is available through various special access programs for the treatment of Urinary tract infections in the UK, the Netherlands, Sweden, Norway, Spain, Australia and New Zealand (Red Leaf Medical website, June 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top